Clinical Trials Sponsored by Cebix Incorporated

Total 1173 results

Bausch & Lomb Incorporated

Completed

Study of T-PRED(TM) Compared to Pred Forte(R)

Cataract

United States
Bausch & Lomb Incorporated

Completed

Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery

Inflammation | Cataract

United States
Bausch & Lomb Incorporated

Completed

Safety and Efficacy of an Ophthalmic Solution in Dry Eye Disease

Dry Eye Disease

United States
Bausch & Lomb Incorporated

Completed

Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease

Dry Eye Disease

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Spain, Germany, Italy, Austria, Belgium, Denmark
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, Ireland, Australia, Israel, United Kingdom, Germany, Switzerland, Canada, Denmark, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

Cystic Fibrosis

Israel
Campbell University, Incorporated

Completed

Effectiveness of Reduced Frequency Physical Therapy in Total Knee Arthroplasty

Knee Osteoarthritis | Knee Arthritis | Knee Arthropathy

United States
Bausch & Lomb Incorporated

Terminated

Tear Evaluation Between Habitual Contact Lens Wearers and Non Contact Lens Wearers

Dry Eye

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Cystic Fibrosis

Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Cystic Fibrosis

United States, Spain, Australia, United Kingdom, Germany, Ireland
Cook Group Incorporated

Completed

Retrospective Review of the Cook Biodesign® Fistula Plug to Treat Anorectal Fistulas

Anorectal Fistula

United States, Germany
Bausch & Lomb Incorporated

Completed

Product Performance of a Daily Disposable Contact Lens

Myopia

Singapore
Bausch & Lomb Incorporated

Completed

Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant

Inflammation | Uveitis

United States
Bausch & Lomb Incorporated

Terminated

Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment

Vitreoretinal Traction Syndrome

United States
Bausch & Lomb Incorporated

Completed

Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)

Anaphylaxis

Germany
GlycoMimetics Incorporated
Celerion

Completed

Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers

Healthy

United States
Torax Medical Incorporated

Completed

The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease (CALIBER)

GERD Gastroesophageal Reflux Disease

United States
Vertex Pharmaceuticals Incorporated

Approved for marketing

Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Terminated

A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

Cystic Fibrosis

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Cystic Fibrosis

United States, United Kingdom, Germany, Spain, Switzerland, Canada, Netherlands, Italy, Ireland, Sweden, France, Denmark
Vertex Pharmaceuticals Incorporated

Completed

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

Cystic Fibrosis

United States
Cook Group Incorporated

Completed

PRESERVE-Zenith® Iliac Branch System Clinical Study

Aorto-iliac Aneurysms | Iliac Aneurysms

United States
Cook Group Incorporated

Completed

FORMAT Clinical Study

Symptomatic Vascular Disease of the Iliac Arteries

United States
Cook Group Incorporated

Completed

Hemostasis of Active Gastrointestinal (GI) Luminal Tract Bleeding (HALT)

Bleeding Peptic Ulcers

United Kingdom, Hong Kong, Canada, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Cystic Fibrosis | Advanced Lung Disease

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
Gen-Probe, Incorporated

Terminated

Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays

Gonorrhea | Chlamydia Infections | Trichomonas Infections

United States
Cook Group Incorporated

Completed

Ureteral Stent Study

Urolithiasis

Hong Kong
Cook Group Incorporated

Withdrawn

Antimicrobial Hernia Repair Device

Incisional Hernias | Ventral Hernias
Gen-Probe, Incorporated

Completed

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

Human Papillomavirus Infection

United States
DMF Medical Incorporated

Completed

A New and Innovative Method for CO2 Removal in Anesthetic Circuits: Replacing Chemical Granulate

CO2 Removal | End Tidal CO2

Canada
Cook Group Incorporated

Terminated

ECM and Blood Components for Wound Healing

Ulcer | Foot Ulcer, Diabetic | Venous Ulcer

Canada
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Hepatitis C | Chronic Hepatitis C | HCV | CHC

New Zealand
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, Germany, Canada, Netherlands, Czech Republic, Italy, Ireland, Sweden, United Kingdom, Australia, France
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

Cystic Fibrosis

United States, Belgium, Canada, Netherlands, Germany
Vertex Pharmaceuticals Incorporated

Terminated

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype (CONCISE)

Hepatitis C, Chronic

United States, Austria, Canada, Germany, Israel, Poland
Bausch & Lomb Incorporated

Completed

Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis

Bacterial Conjunctivitis
Bausch & Lomb Incorporated

Completed

Performance Evaluation of Contact Lenses Among a Population of Adapted Contact Lens Wearers

Vision Disorders

United States
Bausch & Lomb Incorporated

Withdrawn

A Study Of The Safety And Effectiveness Of A New Treatment For Allergic Conjunctivitis

Allergic Conjunctivitis
Bausch & Lomb Incorporated

Completed

A Study to Evaluate a New Silicone Hydrogel Contact Lens

Myopia

United States
Cook Group Incorporated

Completed

Zilver® PTX™ Global Registry

Peripheral Arterial Disease | Peripheral Vascular Disease

Germany, Italy
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C

Chronic Hepatitis C

United States, Puerto Rico
Bausch & Lomb Incorporated

Completed

A Study to Evaluate the Product Performance of a Daily Disposable Contact Lens

Myopia | Contact Lenses

United States
Bausch & Lomb Incorporated

Completed

A Study to Evaluate the Product Performance of the PureVision®2 High Definition (HD) Contact Lens

Myopia

United States
Inflamax Research Incorporated

Completed

A Study To Investigate The Effects Of A Low Humidity Environment And Visual Tasking On Tear Film Protein Composition

Dry Eye

Canada
Vertex Pharmaceuticals Incorporated

Completed

Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects

Healthy | Hepatic Impairment

Slovakia, Czech Republic
Cook Group Incorporated

Completed

Treatment of Colonic Obstruction With Cook Evolution® Colonic Stent System

Large Bowel Obstruction | Colonic Obstruction | Colonic Stricture

France, Spain, Denmark, Netherlands, Canada, Italy, United Kingdom
Bausch & Lomb Incorporated

Completed

One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction

Cataract | Aphakia

United States

3

Subscribe